Today: 30 June 2026
Rigetti stock slides as quantum-computing trade cools into year-end

Rigetti stock slides as quantum-computing trade cools into year-end

NEW YORK, December 29, 2025, 11:49 ET — Regular session

  • Rigetti shares fell about 3% in morning trade as quantum-computing stocks stayed volatile into year-end.
  • Recent swings in the group have been driven by profit-taking, thin holiday volumes and valuation concerns, Investors Business Daily reported.
  • Traders are watching for updates tied to Rigetti’s late-2025 technology milestone and the next earnings timeline.

Rigetti Computing’s shares fell about 3% on Monday, extending a late-December pullback in quantum-computing stocks as traders booked gains and waited for fresh catalysts.

The moves matter now because the quantum group has become a momentum trade into year-end, where lighter holiday liquidity can magnify swings in high-volatility names. Investors Business Daily said the sector’s recent slide followed a brief pop earlier this month that arrived “without major news,” and was later met by profit-taking and valuation jitters. Investors.com

Rigetti has drawn attention alongside peers such as IonQ and D-Wave, but much of the day-to-day trading has been driven by shifting sentiment toward the whole theme rather than a single company headline. Investors have been reassessing how quickly early-stage quantum companies can turn research progress into repeatable revenue.

Rigetti (RGTI.O) was down $0.66 at $21.72, after trading between $22.55 and $21.54. About 14.6 million shares had changed hands by late morning.

IonQ (IONQ.N) was down about 1.4% and Quantum Computing Inc (QUBT.O) was down about 2.6%, while D-Wave Quantum (QBTS.N) was up roughly 0.5%.

Quantum computers use “qubits” — the quantum version of a bit — which can in theory tackle certain problems faster than classical machines. For now, most pure-play quantum firms generate uneven revenue and rely heavily on R&D spending, which can leave their stocks sensitive to shifts in risk appetite. Investors.com

Rigetti’s most recent detailed update came with its third-quarter results filing in November, when it reported $1.9 million in revenue and an operating loss of $20.5 million for the quarter. The company said cash, cash equivalents and available-for-sale investments totaled $558.9 million as of Sept. 30, and about $600 million as of Nov. 6, helped by warrant exercises.

Investors have also been focused on whether Rigetti can deliver on near-term performance targets. “We remain on track to deliver our 100+ qubit chiplet-based quantum system … by the end of 2025,” Chief Executive Subodh Kulkarni said in the earnings release. SEC

Two-qubit gate fidelity — a common benchmark in quantum computing — measures how accurately the machine performs operations involving two qubits, with higher percentages indicating fewer errors. Rigetti has said it expects 99.5% median two-qubit gate fidelity for its 100+ qubit system.

In the same release, the company laid out targets for a 150+ qubit system by around the end of 2026 with 99.7% median two-qubit gate fidelity, and a 1,000+ qubit system by around the end of 2027 with 99.8% median two-qubit gate fidelity.

On the commercial side, Rigetti has pointed to purchase orders totaling about $5.7 million for two 9-qubit Novera systems, with delivery expected in the first half of 2026. The company has also highlighted government-backed work, including a $5.8 million Air Force Research Laboratory contract with QphoX, as it looks to build out networking capabilities for superconducting quantum systems.

Traders are watching whether the stock stabilizes after hitting $21.54 at its session low, and whether the group gets any new catalyst beyond year-end repositioning. The next major scheduled check-in is earnings: Zacks expects Rigetti’s next report around March 4, 2026, though the company has not announced a date.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Abivax Jumps 36% After Cancer Safety Fear Eases for Obefazimod
    June 30, 2026, 8:33 AM EDT. Abivax shares climbed 35.77% to 113.10 euros in Paris after new data on its ulcerative colitis drug obefazimod eased cancer safety worries. The updated look, now covering 1,704 patient-years, showed cancer rates tracking with what's expected for the disease, and helped shore up obefazimod's safety profile. Shares had been under pressure after the 50 mg group in Phase 3 turned up higher malignancy numbers. Safety focus stayed high but efficacy held up, with remission topping 50% across doses and relapses. Abivax targets a U.S. FDA filing in the fourth quarter of 2026. In U.S. extended trading, shares picked up 26.4%, narrowing their year-to-date decline to 6.06%.
Tesla stock slips as supplier guts $2.9 bln battery deal to $7,386
Previous Story

Tesla stock slips as supplier guts $2.9 bln battery deal to $7,386

Apple stock slips into 2026 as year-end tech pullback bites; AAPL earnings next
Next Story

Apple stock slips into 2026 as year-end tech pullback bites; AAPL earnings next

Go toTop